Trial Profile
Continuous Access to Advanced and Metastatic Renal Cell Carcinoma Therapy With Everolimus Post Pazopanib Treatment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms CATChEz
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Feb 2018 Results assessing safety, efficacy and pharmacodynamics presented at the 2018 Genitourinary Cancers Symposium
- 26 Sep 2017 Status changed from active, no longer recruiting to discontinued.
- 01 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Nov 2016.